Evaluation of p16/Ki-67 dual staining in detection of cervical precancer and cancers: a multicenter study in China

Lu-Lu Yu, Wen Chen, Xiao-Qin Lei, Yu Qin, Ze-Ni Wu, Qin-Jing Pan, Xun Zhang, Bai-Feng Chang, Shao-Kai Zhang, Hui-Qin Guo and You-Lin Qiao

1 Department of Cancer Epidemiology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China
2 Department of Pathology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China
3 Department of Cancer Epidemiology, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Henan Office for Cancer Control and Research, Zhengzhou, P. R. China

Correspondence to: Hui-Qin Guo, email: ghqin2006@163.com
Correspondence to: You-Lin Qiao, email: qiaoy@cicams.ac.cn

Keywords: cervical cancer; p16/Ki-67 dual staining; human papillomavirus; Chinese women; Pathology Section

Received: December 23, 2015  Accepted: March 10, 2016  Published: March 23, 2016

ABSTRACT

Purpose: To analyze the clinical performance of p16/Ki-67 dual-stained cytology identifying high-grade cervical intraepithelial neoplasia (CIN2+) in Chinese women.

Methods: 1079 women attending ongoing cervical cancer screening and 211 “enriched” women aged ≥30yrs with biopsy-confirmed CIN2+ from five Chinese hospitals were enrolled during year 2014-2015. Cervical specimens were collected for high-risk human papillomavirus (HR-HPV) DNA analysis, Liquid-based cytology (LBC) and p16/Ki-67 dual staining. Colposcopy and biopsy were performed on women with any abnormal result.

Results: p16/Ki-67 positivity increased with histologic severity. It was 18.4%(183/996) in normal histology, 54.0%(34/63) in CIN1, 81.0%(34/42) in CIN2, 93.3%(111/119) in CIN3, 71.4% (5/7) in adenocarcinoma and 95.2%(60/63) in squamous cell carcinoma. Compared with the HR-HPV negatives, p16/Ki-67 expression was significantly higher in the HPV16/18 positive (OR: 35.45(95%CI: 23.35-53.84)) and other 12 HR-HPV types positive group (OR: 8.01(95%CI: 5.81-11.05). The sensitivity and specificity of p16/Ki-67 to detect CIN2+ in the entire population were 90.9% and 79.5%, respectively. In women with ASC-US and LSIL, sensitivity and specificity for detection of CIN2+ were 87.5% and 66.4%, respectively, with a referral rate of 43.8%. In women who tested positive for HR-HPV, sensitivity and specificity of dual-staining for detection of CIN2+ were 92.7% and 52.7%, respectively, and the referral rate was 68.7%.

Conclusions: p16/Ki-67 dual-stained cytology provided a high sensitivity and moderate specificity to detect underlying cervical precancer and cancers in various settings, and might be considered as an efficient screening tool in China.

INTRODUCTION

As the most populous country in the world, the disease burden of cervical cancer varies greatly in China due to the unbalanced development of economy, uneven distribution of its population and screening coverage. More than 70% of the Chinese population living in rural areas where 90% of incident cervical cancer estimate to occur, however, cervical cancer screening is mainly available in cities, rural Chinese women receive minimal benefit from screening improvement [1]. From 2009 to 2015, the Chinese government launched a nationwide free cervical cancer screening project for 40 million rural women by using visual inspection with acetic acid (VIA)
and cytology based screening methods, however, with an estimation of 500 million women in rural areas, cervical cancer remains a critical problem threatening women’s health.

Papanicolaou (Pap) cytology is widely used for cervical cancer screening since its introduction to China in 1999. However, the positive prediction of atypical squamous cells of undetermined significance (ASC-US) and low-grade intraepithelial lesions (LSIL) cytology results for the presence of high-grade cervical intraepithelial neoplasia (HG CIN) is relatively low, with a 5-year risk for cervical intraepithelial neoplasia grade 3 or worse (CIN3+) of 2.6% and 5.2%, respectively [2]. So a method to identify women who harboring HG CIN with ASCUS/LSIL cytology is highly needed.

In resource limited rural areas in China, it is difficult to build the infrastructure necessary for a successful Pap cytology screening system. Alternative screening strategies have been developed, including molecular testing for HR-HPV -the necessary cause of cervical cancer. HR-HPV DNA testing has been evaluated and shown to be more sensitive and reliable than Pap cytology [3-7]. In April 2014, the FDA approved the use of an HPV test (the cobas HPV Test) for primary cervical cancer screening for women aged 25 years and older. However, though a negative HPV result can almost exclude that women have precancer or cancer [8, 9], 80%-90% of women who tested positive will not have concurrent diseases. Limited resources need to be prioritized for women at the highest risk for harboring cancer, the management of screen-positive women is a coming issue.

\( p^{16\text{INK4a}} \) (p16) is a cyclin-dependent kinase inhibitor that has been proven to be strongly overexpressed in transforming infections with oncogenic types of HPV and is believed to be a surrogate marker for precancerous cervical lesions [10, 11]. However, overexpression of p16 may not only be observed in dysplastic cells but also in tubal metaplasia and endometrial cells as well as in normal columnar cells from the cervix, which raises challenge in examining cytological samples. Ki-67 is a nuclear antigen and a cellular proliferation marker expressed in all cell-cycle phases except G0, which is also overexpressed in HG CIN [12]. In normal cells, the expression of p16 and Ki-67 is mutually exclusive. Hence, it is thought that the simultaneous detection of p16 overexpression and Ki-67 within a cell would be indicative of deregulation of the cell cycle and a transforming HPV infection which may progress to cancer. The CINtec PLUS Cytology test (Roche Tissue Diagnostics/Ventana Medical Systems, Inc., Tucson, AZ, USA) is an immunocytochemical cocktail composed of antibodies against p16 and Ki-67. Many studies have been conducted to assess the clinical utility of p16/Ki-67 dual-staining for the detection of HG CIN in primary cervical screening or in ASCUS/LSIL triage as well as for the triage of Pap cytology-negative, HPV positive screening results [13-15], but no such data were available in China. We performed this study to evaluate the clinical utility of p16/Ki67 as a marker for detecting cervical precancer and cancer in a combined population of women referred from colposcopy clinics and from a screening program.

**RESULTS**

A total of 1,357 Chinese women were enrolled. Of them, 35 (2.6%) women were excluded due to incomplete histology results, 32 (2.4%) women were excluded because of indeterminate cobas HPV Test results or unsatisfactory cytology results. A total of 1,290 women were included in the final analysis, including 1,079 (83.6%) women from the screening group. Among them, 481 (44.6%) had abnormal test results and received colposcopy, with 63 CIN1, 14 CIN2 and 6 CIN3 cases. There were 211 women in enriched group, i.e. 16.4% of all women. The mean age of the women included in the analysis was 48.3 ± 8.7 years (range, 30-69 yrs; median: 48 yrs).

As shown in Table 1, the overall test positivity of p16/Ki-67 dual staining (33.1%) was a little lower than that of the HR-HPV (35.9%) and LBC (36.3%) in the whole population \((p < 0.05)\). It increased significantly with disease severity \( \left(P_{\text{red}} < 0.0001 \right) \). There were 996 (77.2%) women with negative histology, 63 (4.9%) with CIN1, 42 (3.3%) with CIN2, 119 (9.2%) with CIN3, 63 (4.9%) with SCC, and 7 (0.5%) with ADC. The corresponding p16/Ki-67 dual staining positivity was 18.4%, 54.0%, 81.0%, 93.3%, 95.2%, and 71.4%, respectively.

To analyze the associations between HR-HPV infection and p16/Ki-67 dual-stain positivity, the participants were divided into three groups according to HPV status. HPV positivity was strongly associated with p16/Ki-67 dual staining in the whole population (Table 2). Compared to HR-HPV negatives, p16/Ki-67 expression in HPV16/18 positive and other 12 HR-HPV types positive group was significantly higher, with an odds ratio (OR) of 35.45 (95% CI: (23.35-53.84)) and of 8.01 (95%CI:(5.81-11.05)), respectively. Specifically, when stratified by histology, the association was still significant (all \(p < 0.05\)).

Sensitivities, specificities, PPVs, NPVs, AUCs, and colposcopy referral rates for all screening methods to detect CIN2+ or CIN3+ are shown in Tables 3, 4 and 5. In the whole population, the sensitivity of p16/Ki-67 to detect CIN2+ and CIN3+ were 90.9% and 93.1%, respectively, which were similar with that of HR-HPV and LBC (all \( p > 0.05 \)); the specificity of p16/Ki-67 to detect CIN2+ was similar with that of HR-HPV \((p > 0.05)\), but slightly higher than that of LBC (79.5% vs 76.2%, \( p = 0.042 \)); in detection of CIN3+, the specificity of p16/Ki-67 was not significant different with that of LBC \((p > 0.05)\), but a little higher than that of HR-HPV (77.2% vs 74.1%,
The similar situation was also observed in the screening population. There were 256 women diagnosed as ASC-US or LILS in the whole population, and 48 CIN2+ cases were detected in this group; the p16/Ki-67 positivity was 43.8%, indicating that colposcopy referral would be reduced by more than half if p16/Ki-67 dual-stain were used as a triage test (Table 4). The sensitivity and specificity for detection of CIN2+ were 87.5% and 66.4%, respectively. The sensitivity and specificity for detection of CIN3+ were 89.7% and 62.1%, respectively. Compared to HR-HPV test, p16/Ki-67 dual staining had a similar sensitivity (p = 0.727 and 1.000) for both endpoints, but a higher specificity (p = 0.003 and 0.002).

Four hundred and sixty-three women were tested positive for HR-HPV in the entire population, and there were 218 CIN2+ cases in this group; the performance of HPV16/18 genotyping, LBC and p16/Ki-67 dual staining were evaluated (Table 5). In contrast with HPV16/18 genotyping, p16/Ki-67 had a higher sensitivity (92.7% vs 71.1, p < 0.0001) for CIN2+ and CIN3+(95.0% vs 79.8%, p < 0.0001) but a lower specificitiy for both endpoints(52.7% vs 74.7% for CIN2+, 47.7% vs 73.7% for CIN3+). Notably, the positivity of p16/Ki-67 was 68.7%, which means that more than 30% of women would not need referral to colposcopy if p16/Ki-67 dual staining would be used as a triage.

**DISCUSSION**

To our knowledge, this is the first study to comprehensively evaluate the performance of p16/Ki-67 dual stained cytology in primary screening and as a tool to triage women with ASCUS/LSIL or positive HR-HPV.
Table 2: Association of p16/Ki67 expression and HR-HPV in different histology categories.

|                      | p16/Ki67 positive | p16/Ki67 negative | P Value | OR (95%CI) |
|----------------------|-------------------|-------------------|---------|-------------|
|                      | N (%)             | N (%)             |         |             |
| All                  |                   |                   |         |             |
| HR-HPV negative (n = 827) | 109(13.2)         | 718(86.8)         | -       | Ref         |
| Other 12 HR-HPV positive (n = 246) | 135(54.9)         | 111(45.1)         | <0.001  | 8.01(5.81-11.05) |
| HPV16/18 positive (n = 217) | 183(84.3)         | 34(15.7)          | <0.001  | 35.45(23.35-53.84) |
| < CIN2               |                   |                   |         |             |
| HR-HPV negative (n = 814) | 101(12.4)         | 713(87.6)         | -       | Ref         |
| Other 12 HR-HPV positive (n = 246) | 79(43.2)           | 104(56.8)         | <0.001  | 5.36(3.74-7.68) |
| HPV16/18 positive (n = 62) | 37(59.7)           | 25(40.3)          | <0.001  | 10.45(6.04-18.08) |
| CIN2+                |                   |                   |         |             |
| HR-HPV negative (n = 13) | 8(61.5)            | 5(38.5)           | -       |             |
| Other 12 HR-HPV positive (n = 63) | 56(88.9)          | 7(11.1)           | 0.021   | 5.00(1.28-19.60) |
| HPV16/18 positive (n = 155) | 146(94.2)         | 9(5.8)            | 0.001   | 10.14(2.75-37.37) |

aAbbreviations: OR, Odds ratio; CI, confidence interval; CIN2+, cervical intraepithelial neoplasia grade 2 or worse.
bother 12 HR-HPV positive: positive for any of the 12 HPV types(HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68), and negative for HPV16/18.

Table 3: Clinical performance characters of p16/Ki67 dual staining, HR-HPV test and LBC for detection of CIN2+ or CIN3+ in entire population.

|                      | Sensitivity (95%CI) | Specificity (95%CI) | PPV (95%CI) | NPV (95%CI) | AUC (95%CI) |
|----------------------|---------------------|---------------------|-------------|-------------|-------------|
| CIN2+                |                     |                     |             |             |             |
| Total population(CIN2+=231) |                   |                   |             |             |             |
| p16/Ki67             | 90.9(86.5-94.0)     | 79.5(77.0-81.8)    | 49.2(44.5-53.9) | 97.6(96.3-98.4) | 0.852(0.826-0.878) |
| HR-HPV               | 94.4(90.6-96.7)     | 76.9(74.2-79.3)    | 47.1(42.6-51.6) | 98.4(97.3-99.1) | 0.856(0.832-0.880) |
| LBC                  | 93.5(89.6-96.0)     | 76.2(73.6-78.7)    | 46.2(41.7-50.7) | 98.2(97.0-98.9) | 0.849(0.824-0.873) |
| Screening population(CIN2+ =20) |               |                   |             |             |             |
| p16/Ki67             | 75.0(53.1-88.8)     | 79.5(77.0-81.8)    | 6.5(4.0-10.4) | 99.4(98.6-99.8) | 0.773(0.662-0.883) |
| HR-HPV               | 100.0(83.9-100.0)   | 76.9(74.2-79.3)    | 7.5(4.9-11.4) | 100.0(99.5-100.0) | 0.884(0.851-0.917) |
| LBC                  | 65.0(43.3-81.9)     | 76.2(73.6-78.7)    | 4.9(2.9-8.2) | 99.1(98.2-99.6) | 0.706(0.584-0.829) |
| CIN3+                |                     |                     |             |             |             |
| Total population(CIN3+ =183) |                 |                   |             |             |             |
| p16/Ki67             | 93.1(88.6-96.0)     | 77.2(74.6-79.6)    | 41.2(36.7-45.9) | 98.5(97.4-99.1) | 0.852(0.825-0.878) |
| HR-HPV               | 94.2(89.9-96.7)     | 74.1(71.5-76.6)    | 38.4(34.1-43.0) | 98.7(97.6-99.3) | 0.841(0.815-0.867) |
| LBC                  | 97.4(94.0-98.9)     | 74.2(71.5-76.7)    | 39.3(35.0-43.8) | 99.4(98.6-99.7) | 0.858(0.835-0.880) |
| Screening population(CIN3+ =6) |              |                   |             |             |             |
| p16/Ki67             | 83.3(43.7-97.0)     | 78.8(76.3-81.2)    | 2.2(1.0-4.9) | 99.9(99.3-99.9) | 0.811(0.638-0.984) |
| HR-HPV               | 100.0(61.0-100.0)   | 75.9(73.2-78.3)    | 2.3(1.0-4.9) | 100.0(99.5-100.0) | 0.879(0.821-0.937) |
| LBC                  | 83.3(43.7-97.0)     | 75.8(73.1-78.2)    | 1.9(0.8-4.3) | 99.9(99.3-99.9) | 0.796(0.622-0.969) |

aAbbreviations: CIN2+, cervical intraepithelial neoplasia grade 2 or worse; CIN3+, cervical intraepithelial neoplasia grade 3 or worse; LBC, liquid-based cytology; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; AUC, area under ROC curve.
In this study, 211 CIN2+ cases were enriched to evaluate the clinical performance of p16/Ki-67 dual staining. We noted that the sensitivity of p16/Ki-67 for the detection of CIN2+ and CIN3+ in the entire population was not significantly different from that of LBC and HR-HPV test (by cobas HPV Test), but the specificity was slightly higher than that of LBC in detection of CIN2+ and HR-HPV in detection of CIN3+. It is inconsistent with previous study [13]. The possible explanation might be the different population and different Pap or HPV tests were used in these two studies. Furthermore, it is important to notify that all the Pap cytological diagnoses were made by experienced cytologists in CICAMS [22], which makes it incomparable with other studies.

All women with ASC-US and LSIL results were evaluated by biopsy in this study, allowing us to analyze the performance of p16/Ki-67 for triage of these cytology categories. For these women, p16/Ki-67 achieved sensitivity equal to HR-HPV test but with significantly improved specificity, which lead to 50% decrease to colposcopy. Our findings support that p16/Ki-67 can be a viable option for the triage of equivocal and mildly abnormal Pap cytology results, and this is consistent with previous, mostly retrospective studies or studies performed within a colposcopy clinic [16, 23-26].

Primary HPV DNA testing is believed to be efficient in cervical cancer screening, especially in China, where trained cytopathologists and health care workers are in great shortage. The challenge for HPV DNA testing as primary screening is its lower specificity. Strategies are needed to prioritize women at high cancer risk for immediate intervention. So far, several triage options were considered, including Pap cytology, HPV-genotyping, HR-HPV E6/E7 mRNA or oncoproteins test, or the use of other biomarkers to detect underlying HG CIN, such as p16/Ki-67. Previous studies have been performed to evaluate p16/Ki-67 as a triage marker for HPV-positive women with normal cytology [15, 27]. Our study assessed the accuracy of p16/Ki-67 for the detection of precancer and cancer in HR-HPV positive women with complete disease ascertainment. The sensitivity of p16/Ki-67 for the detection of CIN2+ tends to be higher compared to HPV16/18 genotyping (92.7% vs. 71.1%) and the specificity was significantly lower (52.7% vs. 74.7%). Importantly, p16/Ki-67 could cut the referral rate by more than 30% compared with immediately referring of all HR-HPV positive women to colposcopy. Furthermore, there was no significant difference between the performance of p16/Ki-67 and LBC. However, in rural areas of China, where skilled cytopathologists are not available, the broad use of LBC is unrealistic. Interestingly, the recent published studies showed that the interpretation of p16/Ki-67 dual staining could be performed by staff not trained in the morphological interpretation of cytology after a short training phase, and the experimental reproducibility is quite good [28, 29], indicating the possible use of p16/Ki-67 to triage HR-HPV positive women in low or middle-income countries.

With regard to a study weakness, it is important to
note that this study was conducted in a mixed population including women who attended cervical cancer screening or referred from colposcopy to enrich for CIN2+ endpoints. Hence, the results are not generalizable to the intended-use screening population. Furthermore, the current study focused on the cross-sectional assessment of the performance of p16/Ki-67 dual-stained cytology, which does not allow the evaluation of the long-term risk of HG CIN in women with negative results in the study. However, two recently published retrospective studies have shown a high long-term NPV of negative p16/Ki-67 in HPV-positive women [27, 30]. Finally, since we cannot rule out verification bias using these three tests, the sensitivity of each test may be overestimated.

In summary, in a large referral and screening combined population with excellent disease ascertainment due to a rigorous colposcopy/biopsy protocol, we found that p16/Ki-67 dual-stained cytology is promising to be used for the efficient detection of cervical precancer and cancers in various settings. Future studies are needed to investigate the management algorithm to meet local needs in terms of financial and human resources, infrastructure and capacities, societal norms and level of cancer risk reduction desired.

**MATERIALS AND METHODS**

**Study population and procedures**

This is a population based multicenter (n = 5 centers) study. It was approved by the Institutional Review Board at each participating center (Cancer Institute/Hospital, Chinese Academy of Medical Sciences(CICAMS); Shanxi Cancer Hospital; The Second Affiliated Hospital, Sichuan University; Tianjin Central Hospital of Gynecology and Obstetrics, Henan cancer hospital). The methods were carried out in accordance with the approved guidelines. From April 2014 to March 2015, women who were attending cervical cancer screening (screening group) and women who were referred for colposcopy based on one or more prior abnormal Pap test results or a positive

| Table 4: Clinical performance characteristics of p16/Ki67 dual staining and HR-HPV test for detection of CIN2+ or CIN3+ in women with ASC-US and LSIL. |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                | Sensitivity     | Specificity     | PPV             | NPV             | AUC             | Referral Rate   |
|                | % (95% CI)      | % (95% CI)      | % (95% CI)      | % (95% CI)      | (95% CI)        | % (95% CI)      |
| CIN2+          |                 |                 |                 |                 |                 |                 |
| P16/Ki-67      | 87.5 (75.3-94.1)| 66.4 (59.7-72.4)| 37.5 (29.1-46.7)| 95.8 (91.2-98.1)| 0.769 (0.701-0.838)| 43.8 (40.7-46.9)|
| HR-HPV         | 91.7 (80.5-96.7)| 55.8 (49.0-62.4)| 32.4 (25.1-40.6)| 96.7 (91.7-98.7)| 0.737 (0.669-0.805)| 53.1 (50.0-56.2)|
| CIN3+          |                 |                 |                 |                 |                 |                 |
| P16/Ki-67      | 89.7 (73.6-96.4)| 62.1 (55.7-68.2)| 23.2 (16.4-31.8)| 97.9 (94.1-99.3)| 0.759 (0.679-0.839)| 43.8 (40.7-46.9)|
| HR-HPV         | 89.7 (73.6-96.4)| 51.5 (45.1-58.0)| 19.1 (13.4-26.5)| 97.5 (92.9-99.2)| 0.706 (0.620-0.792)| 53.1 (50.0-56.2)|

a Abbreviations: CIN2+, cervical intraepithelial neoplasia grade 2 or worse; CIN3+, cervical intraepithelial neoplasia grade 3 or worse; LBC, liquid-based cytology; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; AUC, area under ROC curve.

| Table 5: Clinical performance characteristics of p16/Ki67 dual staining, HPV16/18 and LBC for detection of CIN2+ or CIN3+ in women who tested positive for HR-HPV. |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                | Sensitivity     | Specificity     | PPV             | NPV             | AUC             | Referral Rate   |
|                | % (95% CI)      | % (95% CI)      | % (95% CI)      | % (95% CI)      | (95% CI)        | % (95% CI)      |
| CIN2+          |                 |                 |                 |                 |                 |                 |
| P16/Ki-67      | 92.7 (88.4-95.4)| 52.7 (46.4-58.8)| 63.5 (58.1-68.6)| 89.0 (82.8-93.1)| 0.727 (0.680-0.773)| 68.7 (66.5-70.9)|
| HPV16/18       | 71.1 (64.8-76.7)| 74.7 (68.9-79.7)| 71.4 (65.1-77.0)| 74.4 (68.6-79.4)| 0.729 (0.682-0.776)| 46.9 (44.6-49.2)|
| LBC            | 94.5 (90.6-96.8)| 53.5 (47.2-59.6)| 64.4 (59.0-69.4)| 91.6 (85.9-95.1)| 0.740 (0.694-0.785)| 69.1 (67.0-71.2)|
| CIN3+          |                 |                 |                 |                 |                 |                 |
| P16/Ki-67      | 95.0 (90.7-97.3)| 47.7 (42.0-53.5)| 53.1 (47.7-58.6)| 93.8 (88.6-96.7)| 0.713 (0.667-0.759)| 68.7 (66.5-70.9)|
| HPV16/18       | 79.8 (73.3-85.0)| 73.7 (68.3-78.5)| 65.4 (58.9-71.5)| 85.4 (80.4-89.2)| 0.767 (0.722-0.813)| 46.9 (44.6-49.2)|
| LBC            | 98.3 (95.2-99.4)| 49.1 (43.4-54.9)| 54.7 (49.2-60.1)| 97.9 (94.0-99.3)| 0.737 (0.693-0.781)| 69.1 (67.0-71.2)|

a Abbreviations: CIN2+, cervical intraepithelial neoplasia grade 2 or worse; CIN3+, cervical intraepithelial neoplasia grade 3 or worse; LBC, liquid-based cytology; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; AUC, area under ROC curve.
HR-HPV test result or other clinical suspicion of cervical cancer with local biopsy-confirmed CIN2+ (enriched group) were enrolled. All participants need to meet the following criteria: aged 30 years and older, were not pregnant, had a cervix, had not been previously diagnosed with cervical cancer and were able to provide informed consent. Exclusion criteria were previous treatment for cervical diseases (including hysterectomy or destructive therapy). Written informed consent was obtained from all participants. In the screening group, cervical cytology was collected using a cytobrush and transferred to PreservCyt solution (Hologic Inc., Bedford, MA), stored at 4 °C and transported to CICAMS central lab monthly for HPV DNA analysis, Liquid-based cytology (LBC) and p16/Ki-67 dual staining. Women who were positive for any screening test were referred to colposcopy and biopsy. Directed biopsy was taken from all visible cervical lesions, otherwise, the four-quadrant punch biopsy method was indicated; biopsies were taken at positions of 2, 4, 8, and 10 o’clock depending on the quadrant, and endocervical curettage (ECC) was performed. In enriched group, cervical specimens were collected before treatment. Sample collection and processing procedure were the same as for screening group.

**HPV testing**

HR-HPV detection and genotyping was done on a 1ml aliquot removed from cytology specimens before LBC using the cobas HPV Test (Roche Molecular Systems Inc., Pleasanton, CA). The cobas HPV Test features automated sample preparation combined with real-time PCR technology to detect 14 HR-HPV genotypes. PCR amplification and detection occur in a single tube to detect 14 HR-HPV DNA: HPV-16 and HPV-18 individually and the other 12 types pooled (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). All the procedures were performed according to the recommendations of the manufacturer.

**Liquid-based cytology**

Thin-layer cytology slides were prepared with ThinPrep Pap Test (Hologic Inc., Bedford, MA) and stained using the Papanicolaou method. Cytology slides were evaluated by senior cytotechnologists and results were reported according to the Bethesda 2001 classification system. Positive LBC cytology results are defined as atypical squamous cells of undetermined significance (ASC-US) or worse (LBC+), which resulted in referral to colposcopy in the cervical cancer screening group.

**p16/Ki-67 dual staining**

A second cytology slide was prepared from the residual PreservCyt material for p16/Ki-67 which was conducted using the CINtec PLUS Cytology kit (Roche Tissue Diagnostics/Ventana Medical Systems, Inc., Tucson, AZ) according to the manufacturer’s instructions. Samples with one or more cervical epithelial cells that simultaneously showed brownish cytoplasmic immunostaining (p16) and red nuclear immunostaining (Ki-67) were classified as positive regardless of the morphological appearance of the cells. Slides without any double-stained cells were called negative for p16/Ki-67 dual-stain cytology. All the slides were reviewed by a trained cytologist in CICAMS blindly to other tests’ results.

**Histopathology**

Histopathological diagnosis was made by local pathologists firstly, and then all the CIN, HPV DNA negative cervical cancer and adenocarcinoma cases were selected and reviewed by a panel of expert pathologists from each center. The final diagnosis was based on the results of the panel review. Additionally, p16INK4A immunohistochemistry (IHC) staining (Roche Tissue Diagnostics/Ventana Medical Systems, Inc., Tucson, AZ) and progestogen receptor (PR) IHC staining (ZSGB-BIO, Beijing, China) were used as an adjudicator for these selected cases. For the purposes of the study, CIN2, CIN3, squamous cell carcinoma (SCC), and adenocarcinoma (ADC) were referred to as CIN2+ cases, and the other cases were referred to as CIN2- cases.

**Statistical analysis**

The study targeted the recruitment of 196 CIN2+ cases, which with a clinical sensitivity of 85% for CIN2+ would result in a 95% confidence interval of approximately ±5%, i.e., 80% to 90%. Chi square of trend for proportion was calculated to test linear associations between screening methods and increasing severity of cytological and histological diagnoses. Associations between p16/Ki-67 expression and HR-HPV positive were examined using logistic regression models. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated for 2 different endpoints, CIN2+ and CIN3+. Estimates were provided with their 95% confidence intervals (95% CI). In addition, area under ROC curve (AUC) and referral rates to colposcopy based on test positivity were calculated. McNemar tests were used to compare paired matching data such as sensitivities, specificities, fractions of positive results and referral rates between different screening methods. All P values less
than 0.05 (two-sided) were considered to be statistically significant. SPSS 13.0 (SPSS Inc., Chicago, IL, USA) was used for the analyses.

ACKNOWLEDGMENTS

Collaborators of Shanxi Cancer Hospital, The Second Affiliated Hospital, Sichuan University, Tianjin Central Hospital of Gynecology and Obstetrics, Henan cancer hospital and all the women involved in this study are acknowledged for their participance. We also want to thank Dr. Jing Li for her help in revising the manuscript.

CONFLICTS OF INTEREST

All the authors declare that they have no competing interests.

GRANT SUPPORT

This study was supported by a research grant from National Natural Science Foundation of China (grant number: 81272337).

REFERENCES

1. Wen C. China’s plans to curb cervical cancer. Lancet Oncol. 2005; 6:139-141.
2. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC and Kinney WK. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis. 2013; 17:S28-S35.
3. Zhao FH, Lin MJ, Chen F, Hu SY, Zhang R, Belinson JL, Sellors JW, Franceschi S, Qiao YL and Castle PE. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol. 2010; 11:1160-1171.
4. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasiemi P and Iftner T. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006; 119:1102-1107.
5. Fields RP. Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer. N Engl J Med. 2008; 358:642-643, 643-644.
6. Castle PE, Wheeler CM, Solomon D, Schiffman M and Peyton CL. Interlaboratory reliability of Hybrid Capture 2. Am J Clin Pathol. 2004; 122:238-245.
7. Carozzi FM, Del MA, Confortini M, Sani C, Puliti D, Trevisan R, De Marco L, Tos AG, Girlando S, Palma PD, Pellegrini A, Schiboni ML, Crucitti P, Pierotti P, Vignato A and Ronco G. Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting. Am J Clin Pathol. 2005; 124:716-721.
8. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C and Iftner T. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. Bmj. 2008; 337:a1754.
9. Castle PE, Glass AG, Rush BB, Scott DR, Wentzensen N, Gage JC, Buckland J, Rydzak G, Lorincz AT and Wacholder S. Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up. J Clin Oncol. 2012; 30:3044-3050.
10. Wentzensen N and von Knobel DM. Biomarkers in cervical cancer screening. Dis Markers. 2007; 23:315-330.
11. Liao GD, Sellors JW, Sun HK, Zhang X, Bao YP, Jeronimo J, Chen W, Zhao FH, Song Y, Cao Z, Zhang SK, Xi MR and Qiao YL. p16INK4A immunohistochemical staining and predictive value for progression of cervical intraepithelial neoplasia grade 1: a prospective study in China. Int J Cancer. 2014; 134:1715-1724.
12. Nam EJ, Kim JW, Hong JW, Jang HS, Lee SY, Jang SY, Lee DW, Kim SW, Kim JH, Kim YT, Kim S and Kim JW. Expression of the p16 and Ki-67 in relation to the grade of cervical intraepithelial neoplasia and high-risk human papillomavirus infection. J Gynecol Oncol. 2008; 19:162-168.
13. Ikenberg H, Bergeron C, Schmidt D, Griesser H, Alameda F, Angeloni C, Bogers J, Dachre R, Denton K, Hariri J, Keller T, von Knobel DM, Neumann HH, Puig-Tintore LM, Sideri M and Rehm S, et al. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst. 2013; 105:1550-1557.
14. Kisser A and Zechmeister-Koss I. A systematic review of p16/Ki-67 immuno-testing for triage of low grade cervical cytology. Bmj. 2015; 122:64-70.
15. Petry KU, Schmidt D, Scherbring S, Luyten A, Reinecke-Luthge A, Bergeron C, Komsoss F, Loning T, Ordi J, Regauer S and Ridder R. Triageing Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. Gynecol Oncol. 2011; 121:505-509.
16. Wentzensen N, Schwartz L, Zuna RE, Smith K, Mathews C, Gold MA, Allen RA, Zhang R, Dunn ST, Walker JL and Schiffman M. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin Cancer Res. 2012; 18:4154-4162.
17. Dona MG, Vocaturu A, Giuliani M, Ronchetti L, Rollo F, Pescarmona E, Carosi M, Vocaturu G and Benevolo M. p16/Ki-67 dual staining in cervico-vaginal cytology: correlation with histology, Human Papillomavirus detection and genotyping in women undergoing colposcopy. Gynecol Oncol. 2012; 126:198-202.
18. von Knebel DM. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer. 2002; 38:2229-2242.

19. Ghittoni R, Accardi R, Hasan U, Gheit T, Sylla B and Tommasino M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes. 2010; 40:1-13.

20. Castle PE, Schiffman M, Wheeler CM and Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol. 2009; 113:18-25.

21. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW and Skegg DC. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008; 9:425-434.

22. Pan QJ, Hu SY, Guo HQ, Zhang WH, Zhang X, Chen W, Cao J, Jiang Y, Zhao FH and Qiao YL. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China. Gynecol Oncol. 2014; 133:172-179.

23. Ziemke P, Marquardt K and Griesser H. Predictive value of the combined p16 and Ki-67 immunocytochemistry in low-grade squamous intraepithelial lesions. Acta Cytol. 2014; 58:489-494.

24. Bergeron C, Ikenberg H, Sideri M, Denton K, Bogers J, Schmidt D, Alameda F, Keller T, Rehm S and Ridder R. Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results. Cancer Cytopathol. 2015; 123:373-381.

25. Loghavi S, Walts AE and Bose S. CINtec(R) PLUS dual immunostain: a triage tool for cervical pap smears with atypical squamous cells of undetermined significance and low grade squamous intraepithelial lesion. Diagn Cytopathol. 2013; 41:582-587.

26. Schmidt D, Bergeron C, Denton KJ and Ridder R. p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathol. 2011; 119:158-166.

27. Uijterwaal MH, Polman NJ, Witte BI, van Kemenade FJ, Rijkenaar D, Berkhof J, Balfoort-van DMG, Ridder R, Snijders PJ and Meijer CJ. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data. Int J Cancer. 2015; 136:2361-2368.

28. Wentzensen N, Fetterman B, Tokugawa D, Schiffman M, Castle PE, Wood SN, Stienerling E, Poitras N, Lory T and Kinney W. Interobserver reproducibility and accuracy of p16/Ki-67 dual-stain cytology in cervical cancer screening. Cancer Cytopathol. 2014; 122:914-920.

29. Allia E, Ronco G, Coccia A, Luparia P, Macri L, Fiorito C, Maletta F, Deambrogio C, Tunesi S, De Marco L, Gillio-Tos A, Sapino A and Ghiringhello B. Interpretation of p16(INK4a) /Ki-67 dual immunostaining for the triage of human papillomavirus-positive women by experts and nonexperts in cervical cytology. Cancer Cytopathol. 2015; 123:212-218.

30. Uijterwaal MH, Witte BI, Van Kemenade FJ, Rijkenaar D, Ridder R, Berkhof J, Balfoort-van DMG, Bleecker MC, Snijders PJ and Meijer CJ. Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study. Br J Cancer. 2014; 110:1579-1586.